Kornimate/medical-research-clean huggingface dataset:
smartphone for assessing balance in patients with ankle instability

Conditions: Chronic Ankle Instability

Summary: this study aims at investigating the validity and reliability of a smartphone application "myankle: in assessing the balance component of postural control in patients with chronic ankle instability (cai).

lateral ankle sprain (las) is a common injury in athletic and regular activities; with an incidence of 7 per 1000 exposure. after las, residual symptoms may persist leading to chronic ankle instability (cai). this instability is believed to arise from dysfunctional postural control, defective proprioception, weak muscles, or reduced ankle range of motion (rom).thus, assessment of postural control is essential for proper clinical decision-making and treatment selection. with advances in technology, smartphone has been introduced as an assessment tool for the musculoskeletal system. for example, it was used in assessment of rom and mobility in stroke patients and frail elderly conditions. further, it was used to assess balance and falling risk in those population. in addition, it was used to assess balance in healthy and participants with chronic ankle sprain. these studies proved that smartphone is a valid and reliable tool that is light in weight and inexpensive. yet, these studies have some methodological concerns. for example, the application was not validated against gold standard or was validated only in healthy volunteers rather than in patients with musculoskeletal dysfunction. further, a few of these studies did not establish the application discriminative validity between patients and healthy controls. thus, this study will try to answer the following question: "is smartphone application a valid and reliable tool to assess balance in patients with cai compared to gold standards?

Eligibility criteria:
inclusion criteria: 1. adult males and females aging from 18 to 35 years old. 2. referred with a confirmed diagnosis of cai, with a cumberland ankle instability tool score lower than 27 points. 3. had a recurrent sprain within the previous year. exclusion criteria: 1. history of major surgery of lower limb or spine. 2. history of ankle fracture or any other lower limb fracture in the past 2 years. 3. history of lower limb injury 3 months prior to study. 4. presence of problems that affect balance performance as visual or vestibular deficits, neurologic disease, or cerebral concussions during the past 3 months. 5. being currently enrolled in a balance training rehabilitation program. 6. weakness of lower limb musculatures or trunk upon screening muscle testing by the investigator.

Keywords: balance smartphone validity reliability chronic ankle instability
agreement and reliability of transient elastography

Conditions: Chronic Viral Hepatitis

Summary: the aim of this study is to assess agreement, smallest detectable change, and reliability of repeated measurements of liver stiffness of transient elastography in patients with chronic viral hepatitis, and to explore factors associated with disagreement.

previous studies have reported excellent test-retest reliability for transient elastography (te) in viral hepatitis. reliability refers the ability of an instrument to discriminate between study subjects and may be excellent even if considerable measurement-error exists, if the population is heterogenous. agreement, in contrast, refers to differences of measurements on the original scale (kpa for te). whether agreement is acceptable is situation-dependent and can be related to the smallest detectable change (sdc). agreement metrics or sdc have not been addressed in previous studies for chronic viral hepatitis. the aim of this study is to assess agreement, sdc, and reliability of repeated measurements of liver stiffness of te in patients with chronic viral hepatitis, and to explore factors associated with disagreement.

Eligibility criteria:
inclusion criteria: * patients at the departments of infectious diseases in malmö, lund and helsingborg with chronic viral hepatitis. * adult patients * signed informed consent to participate in the study. exclusion criteria: * suspected or confirmed pregnancy. * patients unable to speak swedish * inability to sign informed consent.
clinical observation of ici combined with recombinant human endostatin on leptomeningeal metastasis of lung cancer

Conditions: Leptomeningeal Metastasis; Immune Checkpoint Inhibitor; Endostatin

Summary: immune checkpoint inhibitor combined with recombinant human endostatin can improve the 3-month os rate of leptomeningeal metastasis of lung cancer, and the combination is safe

we will recruit 20 patients with leptomeningeal metastases from lung cancer.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old, gender unlimited; 2. a clear diagnosis of leptomeningeal metastases derived from lung cancer , including positive cerebrospinal fluid cytology and/or neuroimaging diagnosis; 3. a clear history of lung cancer, including histopathological diagnosis, or a combination of cytopathology and imaging; 4. proper organ function (neutrophil count ≥1.5× 109 /l, platelet count ≥100× 109 /l, hemoglobin concentration ≥90g/l, serum transaminase concentration ≤2.5 times the limit of normal value, serum creatinine concentration ≤ 1.5 times the upper limit of normal value, proteinuria ≤1+) 5. dexamethasone ≤2 mg (or equivalent) 7 days before the start of treatment in patients requiring long-term use of the hormone 6. signed the informed consent and was willing to follow the experimental protocol and follow-up exclusion criteria: 1. patients with positive driver genes and effective treatment, such as patients with positive egfr gene sensitive mutation 2. severe infections or serious comorbidities, such as hemorrhagic peptic ulcer, intestinal obstruction, heart failure, kidney failure, or poorly controlled diabetes; 3. be allergic to pd-1 inhibitor and recombinant human endostatin 4. the female patient planned to be pregnant, was pregnant and lactating -
robotic-assisted peripheral intervention for peripheral arterial disease

Conditions: Peripheral Arterial Disease

Summary: this study evaluates the performance of the corpath 200 system to deliver guide wires and balloons to blockages in the arteries of the leg.

the corpath 200 system is currently marketed for remotely delivering guide wires, balloons and stents to blockages in the coronary arteries. this study will evaluate the feasibility of corpath 200 system to deliver guide wires and balloons to blockages in non-coronary arteries. guide wires and balloons are delivered to blockages in the lower limbs manually by doctors.if this study shows that guide wires and balloons can be safely delivered to blockages in the lower limbs, then it will be an alternative for physicians.

Eligibility criteria:
inclusion criteria: * general inclusion 1. at least 18 years of age; 2. symptomatic disease: presence of critical limb ischemia (including tissue loss or rest pain), or lifestyle-limiting claudication requiring intervention in iliac and/or superficial femoral arteries; 3. the subject or the legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent. * angiographic inclusion presence of superficial femoral artery and/or iliac stenosis (\>50%) or occlusion of up to 50 mm in length as determined by angiogram prior to index interventional procedure. exclusion criteria: * general exclusion 1. failure/inability/unwillingness to provide informed consent; 2. target vessel has been previously treated with bypass; 3. has an abdominal aortic aneurysm contiguous with the iliac artery target lesion; 4. has contraindication to anticoagulation; 5. has bleeding or a hypercoagulability disorder; 6. thrombocytopenia; 7. elevated international normalized ratio (\>1.5); 8. elevated serum creatinine (≥2.5 mg/dl); 9. active infection; 10. contraindication to contrast; or 11. enrolled in concurrent clinical study. * angiographic exclusion 1. target vessel: 1. shows evidence of previous dissection or perforation, or 2. has adjacent acute thrombus; 2. lesion is highly calcified; 3. lesion requires use of any atherectomy device during the procedure; 4. has a pre-existing target artery aneurysm or perforation or dissection of the target artery prior to initiation of the interventional procedure.

Keywords: peripheral arterial disease critical limb ischemia claudication percutaneous vascular intervention peripheral vascular intervention
telephone-based cognitive behavioral therapy for bariatric surgery patients: a pilot study

Conditions: Obesity; Eating Disorder

Summary: bariatric surgery is the most effective treatment for patients with extreme obesity. psychological interventions are not routinely offered in bariatric surgery programs. preliminary evidence suggests that cognitive behavioral therapy (cbt) might be effective in reducing binge eating and improving surgical outcomes. the current study will examine whether the addition of telephone-based cbt (tele-cbt) to the usual standard of care is more effective than the usual standard of care alone, and whether it is more effective when delivered prior to or following bariatric surgery.

preliminary research suggests that cbt might be effective in reducing eating pathology and improving surgical outcomes. however, previous studies have examined group-based cbt delivered in person, and most patients cannot feasibly attend weekly therapy appointments at the hospital. telephone-based cbt offers greater convenience because the service can be delivered during the evening and weekends, and eliminates the need to leave work and travel to hospital appointments. no published studies have examined the effectiveness or feasibility of telephone-based cbt for bariatric surgery patients. this study will examine the effectiveness of tele-cbt as an adjunctive treatment to the usual standard of care in bariatric surgery patients.

Eligibility criteria:
inclusion criteria: * fluent in english * have access to telephone and computer with internet access * have the capacity to provide informed consent exclusion criteria: * active suicidal ideation * serious mental illness * active severe depression * active severe anxiety * active post traumatic stress disorder

Keywords: bariatric surgery cognitive behavioral therapy telephone based cbt obesity
a study of the pharmacokinetics, pharmacodynamics, and safety of arc1779 injection in patients with von willebrand disease type 2b

Conditions: Von Willebrand Disease

Summary: to evaluate the effect of arc1779, a therapeutic oligonucleotide ("aptamer") in patients with type2b von willebrand disease.

arc1779 will be investigated in an open-label, uncontrolled study in up to 3 vwd-2b patients. patients with vwd-2b will be screened for eligibility based primarily upon a single major criterion, i.e., presence of any degree of chronic thrombocytopenia. eligible patients will be treated by intravenous infusion of arc1779 for 72 hours.

Eligibility criteria:
inclusion criteria: * male or female patients; * ≥ 16 to ≤ 75 years of age; * diagnosis of vwd-2b according to national expert guidelines for the usa \[1\] and europe \[2\] based on medical history and findings from a matrix of laboratory assays which may include: platelet count, concentration of vwf antigen (vwf:ag), vwf ristocetin cofactor activity (vwf:rco), factor viii (fviii) activity, ristocetin-induced platelet aggregation (ripa), platelet function analyzer (pfa-100®) closure time, bleeding time (bt), vwf multimer test, vwf: platelet-binding (vwf:pb) activity, etc.) * thrombocytopenia (defined as a platelet count \< 100 per nl on at least 2 occasions within the month preceding enrollment; * female patients of reproductive age must be enrolled within 1 to 7 days of the cessation of preceding menses; * female patients must be non-pregnant and willing to use effective, redundant methods of contraception (i.e., for both self and male partner) throughout the study and for at least 30 days after discontinuation of study drug treatment; * male patients must agree to use a medically acceptable contraceptive (abstinence or use of a condom with spermicide) throughout the study and for at least 30 days after discontinuation of study drug treatment; * all patients must be capable of understanding and complying with the protocol and must have signed the informed consent document. exclusion criteria: * patients with a possible co-existing or alternative hematologic diagnosis which can account for the laboratory findings of thrombocytopenia, etc.; * any significant medical co-morbidity which would pose an increased risk of bleeding (e.g., recent trauma or surgery, a history of gastrointestinal ulcers, etc.) or thrombosis (e.g., history of recurrent deep vein thrombosis (dvt).
a study to evaluate medi-524 in children with hemodynamically significant congenital heart disease

Conditions: Congenital Heart Disease

Summary: the primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.

the primary objective was to describe the safety and tolerability of motavizumab when given monthly as prophylaxis against serious rsv infection among children with hemodynamically significant congenital heart disease.

Eligibility criteria:
inclusion criteria: * 24 months of age or younger at randomization (child must have been randomized on or before their 24-month birthday) * documented, hemodynamically significant chd * unoperated or partially corrected chd * written informed consent obtained from the patient's parent(s)/legal guardian(s) note: the following children were not eligible: children with uncomplicated small atrial or ventricular septal defects or patent ductus arteriosus, children with aortic stenosis, pulmonic stenosis, or coarctation of the aorta alone. children with acyanotic cardiac lesions must have pulmonary hypertension \[≥ 40 mmhg measured pressure in the pulmonary artery (pa)\] or the need for daily medication to manage chd. exclusion criteria: * unstable cardiac or respiratory status, including cardiac defects so severe that survival was not expected or for which cardiac transplantation was planned or anticipated * hospitalization, unless discharge was anticipated within 21 days * anticipated cardiac surgery within two weeks of randomization * requirement for mechanical ventilation, extracorporeal membrane oxygenation, continuous positive airway pressure or other mechanical respiratory or cardiac support * associated non-cardiac anomalies or end organ dysfunction resulting in anticipated survival of less than six months or unstable abnormalities of end organ function * acute respiratory illness, or other acute infection or illness note: children with any respiratory symptoms must have had a negative rsv test prior to randomization * chronic seizure or evolving or unstable neurologic disorder * known immunodeficiency * mother with hiv infection (unless the child had been proven to be not infected) * known allergy to ig products * receipt of any polyclonal antibody (for example, hepatitis b ig, ivig, vzig) within 3 months prior to randomization * receipt of palivizumab (synagis®) within 3 months prior to randomization * use of investigational agents within the past three months (other than investigational agents commonly used during cardiac surgery or the immediate post-operative period, e.g., nitric oxide) * current participation in other investigational protocols of drugs or biological agents * previous participation in mi-cp124 (season 1)

Keywords: synagis, motavizumab, palivizumab, children, medi-524, rsv, congenital hear disease
machine learning predictive models for sepsis risk in icu patients with intracerebral hemorrhage

Conditions: Intracerebral Hemorrhage; Sepsis

Summary: patients with intracerebral hemorrhage (ich) in the intensive care unit (icu) are at heightened risk of developing sepsis, significantly increasing mortality and healthcare burden. currently, there is a lack of effective tools for the early prediction of sepsis in ich patients within the icu. this study aims to develop a reliable predictive model using machine learning techniques to assist clinicians in the early identification of patients at high risk and to facilitate timely intervention. the medical information mart for intensive care (mimic) iv database (version 2.2) is an international online repository for critical care expertise. this database contains patient-related information collected from the icus of beth israel deaconess medical center between 2008 and 2019. it includes a vast dataset of 299,712 hospital admissions and 73,181 intensive care unit patients. the eicu collaborative research database (eicu-crd) comprises data from over 200,000 icu admissions for 139,367 unique patients across 208 us hospitals between 2014 and 2015, providing a valuable resource for critical care research. this study aims to establish and validate multiple machine learning models to predict the onset of sepsis in icu patients with ich and to identify the model with the optimal predictive performance.

* data collection: this study utilized two public databases. the model leveraged clinical data obtained from the medical information mart for intensive care (mimic) iv database (version 2.2) and selected corresponding patients for external validation from the eicu collaborative research database (eicu-crd). data on ich patients were extracted from the mimic iv public database, including baseline characteristics, clinical parameters, therapeutic interventions, and outcomes. the data were randomly divided into two groups, with 70% serving as the training set and 30% as the validation set. * model development: feature selection was performed using lasso regression to construct various machine learning models (such as random forest, logistic regression, and neural networks). * model validation: in addition to the internal validation set, external validation was also conducted on the eicu database to test the model's generalizability. * statistical analysis: the predictive performance of the model was evaluated using metrics including the area under the roc curve (auc), sensitivity, and specificity. * clinical applicability assessment: the clinical utility of the model was assessed using decision curve analysis (dca).

Eligibility criteria:
inclusion criteria: * 1. diagnosed with primary intracerebral hemorrhage by icd-9/10 coding. * 2. aged 19-89 years old. exclusion criteria: * 1. patients admitted to the hospital but not to the icu. * 2. patients with missing follow-up data or incomplete variables. * 3. patients with a hospital stay exceeding one month.
hysteroscopic follow-up following conservative stepwise surgical approach for management of placenta previa accreta

Conditions: Placenta Accreta

Summary: conservative management of placenta accreta spectrum can preserve future fertility but should only be done in hospitals with enough experience as it carries a high risk of maternal complications. follow up after conservative management is crucial to detect complications early.

placenta accreta is defined histopathologically as abnormal trophoblast invasion of part or all of the placenta into the myometrium of the uterine wall.1 depending on the depth of villous tissue invasiveness, placenta accreta was subdivided by pathologists into "creta", "increta", and "percreta", in which the villi adhere superficially to the myometrium without interposing decidua, penetrate deeply into the uterine myometrium, and perforate through the entire uterine wall and may invade the surrounding pelvic organs, respectively. the term placenta accreta spectrum (pas) will be used in this manuscript to include both the abnormally adherent and the invasive forms of accreta placentation. severe and sometimes life-threatening hemorrhage, which often requires blood transfusion, increases maternal morbidity and mortality.

Eligibility criteria:
inclusion criteria: 1. pregnant women with one or more previous cesarean deliveries 2. women diagnosed with placenta previa accreta and underwent conservative stepwise surgical approach for management. exclusion criteria: 1. women who refused to participate in the study. 2. associated other medical conditions as pregnancy-induced hypertension, heart diseases, and rheumatological diseases apart from iron deficiency anemia. 3. presence of uterine anomalies
open-angle glaucoma subjects with cataract treated with cataract surgery plus one istent and one istent supra

Conditions: Glaucoma, Open-Angle

Summary: open angle glaucoma subjects with cataract treated with cataract surgery plus one trabecular micro-bypass stent and one suprachoroidal stent


Eligibility criteria:
inclusion criteria: * clinically significant cataract requiring surgery primary open-angle or pseudoexfoliative glaucoma visual field defects no worse than -12db subject on two ocular hypotensive medications at screening medicated iop at screening between 18 and 30 mm hg normal iridocorneal anatomy absence of peripheral anterior synechiae exclusion criteria: * monocular subjects or those with wore than 20/200 vision in fellow eye prior stent implantation, incision glaucoma surgery, or laser trabeculoplasty in study eye traumatic, uveitic, or neovascular glaucoma
evaluation of efficacy of cryotherapy for skin anesthesia during arterial puncture

Conditions: Cryotherapy Effect

Summary: the purpose of this study is to evaluate the cryotherapy effect by vapocoolant spray to reducing pain during puncture for artérial blood gas

blood gas analysis by arterial puncture is the gold standard in the assessment of a patient's acidbase status and oxygenation. this procedure, which can be repeated depending on the clinical condition of patient, is however associated with a potentially painful experience for patients. the known anesthetic properties of cold can be an interesting alternative to evaluate in the reduction of pain induced during arterial puncture for gas analysis in critically il patients.

Eligibility criteria:
inclusion criteria: * all adult patients (age≥18 years) hospitalized in intensive care unit * patient requiering arteriale puncture for abg * a négative score of cam icu scale * patient with a score to visual analog scale \< or equal 30mm * securité sociale affiliated * consentement exclusion criteria: * patient undergoing mechanical ventilation * patient with arterial catheter * patient with arterio veinius fistul * patient receiving topical anesthesic at least 2 h before the puncture * patient with cutaneous lesion (zone of puncture) * raynaud syndrom * cold sensibility * allen test negative * pregnant * legal guardianship

Keywords: cryotherapy vapocoolant spray arterial puncture intensive care unit